Causeway is pioneering a new class of microRNA-based therapies
Learn more
about our phase 2 clinical trial >
What is Tendinopathy?
Tendinopathy is a chronic tendon condition marked by pain and loss of function caused by overuse, degeneration, or repetitive stress. It is hugely burdensome to patients and costly to healthcare systems.
What are microRNAs?
MicroRNAs are small (~22 nucleotides), non-coding RNA molecules that regulate gene expression, influencing cell behavior and tissue repair processes at the molecular level.
Enabling patients to reclaim their active lives
We have discovered that microRNA-29a acts through multiple pathways to treat chronic tendon disease
Underpinned by Nobel Prize winning science, we are committed to helping patients reclaim their active lives. Our Approach
There are currently no approved therapies for tendinopathy.
We're
developing
one:
TenoMiR®
TenoMiR® is a one-time injectable that targets the underlying molecular cause of tendinopathy, promoting tendon repair, improving function and alleviating elbow and shoulder pain.
Repairing and restoring tissue for healthier aging
Our academic founders discovered that injury-induced loss of miR-29a is a master regulator of tendinopathy disease pathways.
Our pipeline programs focus on harnessing microRNA technology to develop innovative therapies for high-impact conditions like tendinopathy, cardiovascular diseases, and skin aging.
